Nuveen
VBIV

Nuveen’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Nuveen’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-19,165
Closed -$174K – 3321
2023
Q1 		$174K Sell
19,165
-1,962
-9% -$27.8K ﹤0.01% 3008
2022
Q4 		$248K Sell
21,127
-2,844
-12% -$50.2K ﹤0.01% 3024
2022
Q3 		$508K Sell
23,971
-403
-2% -$10.9K ﹤0.01% 2960
2022
Q2 		$591K Sell
24,374
-1,424
-6% -$48.5K ﹤0.01% 2976
2022
Q1 		$1.2M Buy
25,798
+139
+0.5% +$6.87K ﹤0.01% 2740
2021
Q4 		$1.69M Sell
25,659
-1,824
-7% -$154K ﹤0.01% 2649
2021
Q3 		$2.73M Buy
27,483
+181
+0.7% +$17.2K ﹤0.01% 2527
2021
Q2 		$2.74M Sell
27,302
-1,806
-6% -$176K ﹤0.01% 2556
2021
Q1 		$2.72M Buy
29,108
+3,299
+13% +$335K ﹤0.01% 2463
2020
Q4 		$2.13M Sell
25,809
-1,103
-4% -$94.1K ﹤0.01% 2475
2020
Q3 		$2.31M Sell
26,912
-197
-0.7% -$23K ﹤0.01% 2306
2020
Q2 		$2.52M Buy
27,109
+5,804
+27% +$320K ﹤0.01% 2239
2020
Q1 		$607K Buy
21,305
+7,437
+54% +$289K ﹤0.01% 2705
2019
Q4 		$575K Buy
13,868
+6,522
+89% +$143K ﹤0.01% 2874
2019
Q3 		$104K Hold
7,346
– – ﹤0.01% 3167
2019
Q2 		$257K Buy
+7,346
New +$398K ﹤0.01% 3138

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen's VBIV Position: Q2 2023 in Review

Nuveen sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2023, closing a stake of 19,165 shares — an estimated $174K sold.

Nuveen first reported a position in VBIV in Q2 2019 and held it in 16 quarters. The position peaked at $2.74M in Q2 2021. 46 funds tracked by Wall St. Rank hold VBIV as of Q2 2023.

  • Nuveen reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2023 after selling out during the quarter.
  • Nuveen sold 19,165 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2023, an estimated $174K.
  • Nuveen first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2019 and held it in 16 quarters.
  • Nuveen's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $2.74M in Q2 2021.
  • 46 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2023.

Based on Nuveen's 13F filing for Q2 2023, filed 14 Aug 2023.